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Abstract: G-quadruplexes (G4s), which are structures formed in guanine-rich regions of DNA,
are involved in a variety of significant biological functions, and therefore “sequence-dependent”
selective G4-stabilizing agents are required as tools to investigate and modulate these functions.
Here, we describe the synthesis of a new series of macrocyclic hexaoxazole-type G4 ligand (6OTD)
bearing three side chains. One of these ligands, 5b, stabilizes telomeric G4 preferentially over the
G4-forming DNA sequences of c-kit and K-ras, due to the interaction of its piperazinylalkyl side chain
with the groove of telomeric G4.
Keywords: macrocyclic oxazole; G-quadruplex; telomere; telomestatin
1. Introduction
G-quadruplex (G4) is one of the characteristic higher-order structures of non-B DNAs [1]. G4-forming
DNA sequences have been found in telomeres, CpG islands, and gene-promoter regions [2–7],
and play critical roles in many biological processes, including replication [8,9], gene transcription [10],
and translation [11–13]. Thus, compounds that selectively stabilize G4s are promising tools for
investigating those functions, as well as candidate therapeutic agents for diseases related to the G4s.
Since the G4 structure consists of two or three G-quartet planes with grooves, most G4 ligands so far
reported have targeted the G-quartet or the grooves [14,15]. For example, the G4 ligands TMPyP4 [16,17],
PhenDC3 [18], and pyridostatin [14,19] interact with the G-quartet in G4, whereas TOxaPy [20] and
distamycin A [21] recognize the groove in telomeric G4.
We have developed a series of macrocyclic hexaoxazoles, called 6OTD [22], as G4 ligands based
upon the structure of the natural G4 ligand telomestatin [23,24]. Among these derivatives, we have
recently shown that 4,2-L2H2-6OTD [25] and L2G2-2M2EG-6OTD [26], obtained by altering the
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connectivity of the oxazoles or by introducing side chains into the 6OTD core structure, interact
selectively with anti-parallel and parallel-type topologies, respectively. Here, we describe the synthesis
of a new series of 6OTD derivatives bearing side chains that recognize both the G-quartet and the
grooves of G4. One of these ligands, 5b, stabilizes telomeric G4 preferentially over the G4-forming
DNA sequences of c-kit and K-ras, due to the interaction of a piperazinylalkyl side chain with the
groove of telomeric G4 [27–31]. Selective stabilization of telomeric G4 would lead to the senescence
and apoptosis of cancer cells through dissociation of telomeric protective proteins such as TRF2 and
POT1 from telomeric DNA [32–36].
2. Results and Discussion
2.1. Design of 6OTD Derivatives for Targeting Telomeric G4
G-quadruplex structures form a variety of topologies depending upon their sequences,
and a promising strategy to design “sequence-dependent” selective ligands [37–39] is to target both
the G-quartet and the G4 grooves. We previously analyzed the interaction mode of L2H2-6M(2)OTD
1 with telomeric DNA by NMR, which is shown in Figure 1a [40], and found that the core structure
of the macrocyclic moiety in 6OTD 1 interacts with the G-quartet of telomeric G4 through a pi-pi
interaction. In addition, the two aminoalkyl side chains in 1 interact with the phosphate backbone of
DNA. Notably, the architecture, as shown in Figure 1a, includes an additional potential ligand-binding
site, i.e., the groove circled in blue. Thus, based on the structure depicted in Figure 1b, we designed
tri-substituted 6OTD 2, which has an additional side chain at C5 of L2H2-6M(2)OTD 1. We expected
that this modification would increase the affinity for telomeric G4 and the specificity of the interaction.
Specifically, we designed three types of novel tri-substituted L2H2-6OTD derivatives 3–5, bearing
an aminoethyl group, an aminoethoxyethyl group, and a piperazinyethoxyethyl group at C5 in 2,
respectively, and examined their specific interactions with telomeric DNA, as shown in Figure 2.
Figure 1. (a) Structure of L2H2-6M(2)OTD 1 and its interaction with telomeric G-quadruplex (G4),
as elucidated by NMR analysis; (b) Structure of tri-substituted macrocyclic hexaoxazole (6OTD) 2,
and its possible interaction with telomeric G4.
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Figure 2. Structures of novel 6OTD analogs 3–5 targeting the G-quartet and the groove of telomeric G4.
2.2. Synthesis of Tri-Substituted 6OTD Derivatives 3–5
We synthesized tri-substituted 6OTD derivatives 3–5 as summarized in Schemes 1 and 2. Firstly,
the synthesis of tri-amine 3 was carried out. Briefly, the bis-Boc-protected tri-substituted 6OTD 14
was synthesized from trioxazoles 6 and 8 based upon the procedure developed by our group [41,42].
Then, the two Boc groups in 14 were deprotected with TFA to give tri-amine 3 in 81% yield from 13.
Compounds 4 and 5 were synthesized as follows: The amine 14 was reacted with carboxylic acids 15a
(n = 1) and 15b (n = 2) bearing an azide functional group in the presence of EDCI and HOBt, and the
corresponding amides 16a and 16b were obtained in 42% and 39% yields, respectively. After reduction
of the azide group in 16 under hydrogen in the presence of Pd/C as a catalyst, the resulting amine 17
was deprotected with TFA to give tri-amines 4a and 4b in 94% and 90% yields from 16, respectively. The
tri-substituted L2H2-6OTD derivatives of 5a and 5b, bearing an N-methylpiperazine-substituted side
chain, were synthesized similarly to 4 from amine 14 and carboxylic acids 18a (n = 1) and 18b (n = 2).
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2.3. Stabilization Abilities of 3–5 for G4-Forming DNA Sequences by Fluorescence Resonance Energy Transfer
(FRET) Melting Analysis
Next, the abilities of 3–5 to stabilize telomere, c-kit, and K-ras G4-forming DNA sequences were
compared with that of L2H2-6M(2)OTD 1 by means of FRET melting assay, with results shown in
Table 1 [43]. In the case of telomeric G4, telo21, the ∆Tm value was increased by ligands 3–5 bearing
additional side chains compared with L2H2-6M(2)OTD 1, except for with 5a. In regards to other
G4-forming DNA sequences, slight increases of ∆Tm for c-kit were observed with ligands 3, 4a, and
4b, while significant decreases were observed with 5a and 5b. In the case of K-ras, the ∆Tm values
were slightly decreased with ligands 5a and 5b, respectively. These results suggest that 5b interacts
selectively with telomeric G4 over the G4-forming DNA sequences of c-kit and K-ras, among the ligands
and DNA sequences we examined.
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Table 1. Fluorescence resonance energy transfer (FRET) melting analysis of 6OTDs 3–5 (1.0 µM) with
G4-forming DNA sequences (0.2 µM) *.
DNA
∆Tm Values (◦C)
L2H2-6M(2)OTD (1) 3 4a 4b 5a 5b
telo21 18.1 ± 0.0 23.4 ± 0.1 23.5 ± 0.2 24.4 ± 0.5 18.0 ± 0.9 26.2 ± 0.3
c-kit 18.3 ± 0.4 20.8 ± 0.2 19.5 ± 0.3 20.7 ± 0.1 12.9 ± 0.6 12.1 ± 0.3
K-ras 10.3 ± 0.4 13.0 ± 1.0 11.9 ± 0.2 13.5 ± 0.2 9.0 ± 0.2 8.2 ± 0.4
dsDNA 0.1 ± 0.0 0.0 ± 0.1 0.1 ± 0.0 0.0 ± 0.2 0.0 ± 0.1 0.0 ± 0.1
* Melting temperatures were calculated from the average and SEM of at least three experiments.
2.4. Docking Studies of Ligands 3, 4, and 5b with Telomeric G4
To gain insight into the differences in the stabilizing abilities of 3, 4, and 5b, docking studies with
telomeric G4 were carried out. Since the three topologies of telomeric DNA [44] (i.e., anti-parallel,
hybrid, and parallel) are affected by ionic conditions, solvents, and ligands, we first analyzed the
telomeric G4 topologies induced by ligands 3–5 by means of Circular Dichroism (CD) spectroscopy [45].
As shown in Figure 3, telomeric G4 was induced predominantly into the parallel form in the presence of
ligands 3, 4, and 5b under cation-free conditions. On the other hand, in case of ligand 5a, the telomeric
G4 was induced mainly into parallel-type topology, but did not show a single, distinctive spectrum,
in contrast to the other ligands [46].
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Figure 3. Circular Dichroism (CD) spectra of 3, 4 and 5 in the presence of telomeric G4.
With the CD analysis results in hand, docking studies were carried out between parallel-type
telomeric G4 and ligands 3, 4, and 5b. The docking energies between the ligands and parallel-type
telomeric G4 were calculated, and the distribution of the energies for the top 100 poses is shown
in Figure 4 [47]. In these calculations, 5b mainly showed the lowest-energy docking (ca. −9 to
−10.5 kcal/mol) among the ligands tested. The next lowest energy was found for 4b, followed by 4a,
and 3, which is consistent with the results of the FRET melting analysis, which were shown in Table 1.
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telomeric G4.
Docking models with the lowest energy scores for ligands 3, 4, and 5b are depicted in Figure 5.
In every case, the hexaoxazole moiety in the ligands stacks with the G-quartet, and the newly
introduced side chain is suggested to interact with the groove in the parallel-type telomeric G4.
The two nitrogens of piperazine in the side chain in 5b were suggested to interact efficiently with the
phosphate backbone of DNA, which may contribute to 5b’s potent stabilizing ability for telomeric DNA,
compared to 3 and 4. In the case of 5a, the newly introduced side chain may have an inappropriate
chain length for binding with the groove, resulting in a weak stabilizing ability for parallel-type
telomeric G4.
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3. Materials and Methods
3.1. General
Flash chromatography was performed on Silica gel 60 (spherical, particle size 0.040–0.100 mm;
Kanto Co., Inc., Tokyo, Japan). Preparative-TLC (PLC) was performed using PLC Silica gel 60 F254
(0.5 mm, Merck Ltd., Darmstadt, Germany). Optical rotations were measured on a JASCO P-2200
polarimeter. 1H- and 13C-NMR spectra were recorded on JEOL JNM-AL300 (300 MHz), JEOL JNM-ECX
400 (400 MHz), and JEOL JNM-ECA 500 (500 MHz). The spectra were referenced internally according
to the residual solvent signals of CDCl3 (1H-NMR, δ = 7.26 ppm; 13C-NMR, δ = 77.0 ppm) and
DMSO-d6 (1H-NMR, δ = 2.50 ppm; 13C-NMR, δ = 39.5 ppm). Dates for 1H-NMR were recorded as
follows: Chemical shift (δ, ppm), multiplicity (s, singlet; t, triplet; m, multiplet; br, broad), integration,
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and coupling constant (Hz). Dates for 13C-NMR were reported in terms of chemical shift (δ, ppm).
Mass spectra were recorded on a JEOL JMS-T100LC spectrometer with ESI-MS mode, using MeOH
as solvent.
3.2. Synthesis Methods
Compound 10: To a solution of trioxazole 6 [41] (1.00 g, 1.36 mmol) in THF-H2O (3:1, 80 mL) was
added LiOH·H2O (85.5 mg, 2.04 mmol) at room temperature, and stirred for 30 min. The reaction
was acidified with 3 N HCl to give carboxylic acid 7 as a THF-H2O solution, which was used without
further purification. To a solution of trioxazole 8 [42] (1.20 g, 1.40 mmol) in MeOH-THF (1:3, 80 mL)
was added 10% Pd/C (120 mg), and the mixture was stirred at room temperature under a hydrogen
atmosphere for 10 min. The reaction mixture was filtered through a pad of Celite® (FUJIFILM Wako
Pure Chemical Co., Osaka, Japan) and eluted with CHCl3-MeOH (9:1). The filtrates were concentrated
in vacuo to give an amine 9, which was used without further purification. To a solution of carboxylic
acid 7 (THF-H2O) was added NMM (451 µL, 4.08 mmol), DMT-MM (1.12 g, 4.08 mmol), and amine 9,
and the mixture was stirred at room temperature. After being stirred overnight, to the reaction mixture
was added H2O, and the organic layer was extracted with CHCl3, washed with 1.2 N HCl, dried over
MgSO4, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column
chromatography on silica gel (CHCl3:MeOH = 200:1) to give bistrioxazole 10 (1.20 g, 75%, two steps).
Spectral data for 10: [α]25D = −17.8 (c 1.1, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 8.31–8.27 (m, 4H),
8.06 (d, J = 8.7 Hz, 1H), 7.26–7.21 (m, 5H), 5.90 (m, 1H), 5.47 (m, 1H), 5.33–5.20 (m, 2H), 5.03–4.94 (m,
3H), 4.66–4.57 (m, 3H), 3.95 (s, 3H), 3.73–3.62 (m, 2H), 3.45 (t, J = 6.4 Hz, 2H), 3.10 (br, 4H), 2.71 (s,
3H), 2.26–1.78 (m, 4H), 1.52–1.40 (m, 26H); 13C-NMR (100 MHz, CDCl3) δ 165.0, 161.1, 160.2, 156.3,
155.9, 155.8, 155.2, 151.2, 150.9, 143.8, 141.1, 139.5, 139.2, 139.1, 136.4, 136.1, 134.1, 132.4, 130.5, 129.5,
128.2, 127.8, 127.6, 126.5, 124.3, 117.7, 78.9, 78.8, 77.2, 66.5, 65.8, 54.5, 52.2, 49.0, 46.7, 40.0, 39.8, 38.7,
33.4, 32.5, 29.3, 28.2, 26.7, 22.7, 22.3, 11.6; HRMS (ESI, M + Na) calcd. for C56H67N11O17Na 1188.4614,
found 1188.4628.
Compound 11: To a solution of bistrioxazole 10 (400 mg, 340 µmol) in THF (100 mL) was added
morpholine (298 µL, 3.43 mmol) and Pd(PPh3)4 (118 mg, 100 µmol) at room temperature under argon
atmosphere and stirred for 10 min. The reaction mixture was concentrated in vacuo, and the residue
was purified by column chromatography on silica gel (CHCl3:MeOH = 100:3) to give amine 11 (350 mg,
84%). Spectral data for 11: [α]25D = +5.33 (c 1.4, CHCl3);
1H-NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 8.30
(s, 1H), 8.27 (s, 1H), 8.07 (d, J = 8.7 Hz, 1H), 7.26–7.22 (m, 7H), 5.50–5.44 (m, 1H), 5.24 (br, 1H), 5.04–4.96
(m, 2H), 4.66 (br, 1H), 4.55 (br, 1H), 4.04 (t, J = 6.9 Hz, 2H), 3.95 (s, 3H), 3.75–3.44 (m, 4H), 3.12–3.10 (br,
4H), 2.72 (s, 3H), 2.25–0.86 (m, 30H); 13C-NMR (100 MHz, CDCl3) δ 166.3, 165.1, 161.2, 160.3, 156.3,
155.9, 155.3, 151.1, 143.8, 141.1, 139.6, 139.2, 136.5, 136.1, 134.3, 130.6, 129.6, 128.3, 128.0, 127.7, 79.0, 78.9,
77.2, 70.5, 66.7, 52.3, 49.9, 46.8, 40.2, 40.0, 38.9, 35.4, 32.6, 29.7, 29.3, 28.3, 26.8, 22.9, 22.7, 11.8; HRMS
(ESI, M + Na) calcd. for C52H63N11O15Na 1104.4403, found 1104.4370.
Compound 3: To a solution of 13 (70.0 mg, 66.7 µmol) in MeOH (6 mL) was added 10% Pd/C (50.0 mg),
and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 min. The reaction
mixture was filtered through a pad of Celite® and eluted with CHCl3-MeOH (9:1). The filtrates were
concentrated in vacuo to give amine 14, which was used without further purification. The amine 14
was dissolved in CH2Cl2-TFA (10:1, 11 mL), and the resulting solution was stirred at room temperature
for 10 min. The reaction mixture was concentrated in vacuo to give 3 (38.7 mg, 81%, two steps). Spectral
data for 3: [α]25D = +46.1 (c 1.1, MeOH);
1H-NMR (400 MHz, DMSO-d6) δ 9.14–9.12 (m, 2H), 8.92–8.90
(m, 2H), 8.33–8.27 (m, 2H), 8.15 (br, 2H), 7.75 (br, 4H), 5.45 (dt, J = 12.8, 5.5 Hz, 1H), 5.37 (dt, J = 12.8,
5.5 Hz, 1H), 3.75–3.29 (m, 4H), 2.81–2.73 (m, 7H), 2.11–1.88 (m, 4H), 1.54–1.19 (m, 8H); 13C-NMR (100
MHz, DMSO-d6) δ 164.4, 162.0, 158.9, 158.8, 158.7, 158.3, 155.7, 155.3, 155.1, 154.6, 151.9, 149.8, 142.5,
142.4, 141.8, 141.1, 136.0, 136.0, 129.7, 128.5, 125.9, 123.8, 118.4, 47.2, 47.1, 36.9, 33.3, 26.7, 23.9, 20.9, 11.5;
HRMS (ESI, M + H) calcd. for C33H38N11O8 716.2904, found 716.2918.
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Compound 16a: To a solution of 15a (10.0 mg, 66.6 µmol) in THF-H2O (2:1, 3 mL) was added EDCI
(38.0 mg, 200 µmol) and HOBt (27.0 mg, 200 µmol) at room temperature. After stirring for 1 h,
to the reaction mixture was added amine 14 (61.0 mg, 66.6 µmol). The mixture was stirred for 24 h
and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl3, dried over MgSO4,
and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column
chromatography on silica gel (CHCl3:MeOH = 80:1) to give 16a (29.0 mg, 42%). Spectral data for 16a:
[α]25D = −14.5 (c 0.58, CHCl3); 1H-NMR (300 MHz, DMSO-d6) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H),
8.89 (s, 1H), 8.34-8.27 (m, 2H), 7.98 (t, J = 6.2 Hz, 1H), 6.77 (t, J = 5.2 Hz, 2H), 5.42 (dt, J = 12.4, 7.2
Hz, 1H), 5.32 (dt, J = 12.4, 7.2 Hz, 1H), 3.84 (d, J = 15.5 Hz, 1H), 3.78 (d, J = 15.1 Hz, 1H), 3.61–3.27
(m, 6H), 2.84 (br, 4H), 2.75 (s, 3H), 2.04 (br, 2H), 1.90 (br, 2H), 1.33–1.03 (m, 28H); 13C-NMR (125 MHz,
DMSO-d6) δ 169.0, 164.5, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5, 142.3, 141.7,
141.0, 136.0, 135.9, 129.8, 128.4, 124.8, 124.6, 79.2, 77.2, 69.7, 69.5, 49.8, 47.4, 47.2, 36.6, 33.5, 33.4, 29.2,
28.2, 26.1, 21.1, 11.5; HRMS (ESI, M + Na) calcd. for C47H58N14O14Na 1065.4155, found 1065.4143.
Compound 4a: To a solution of 16a (20.0 mg, 19.2 µmol) in MeOH (4 mL) was added 10% Pd/C
(20.0 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 30 min.
The reaction mixture was filtered through a pad of Celite® and eluted with CHCl3-MeOH (9:1).
The filtrates were concentrated in vacuo to give amine 17a, which was used without further purification.
The amine 17a was dissolved in CH2Cl2-TFA (2:1, 3 mL), and the resulting solution was stirred at
room temperature for 10 min. The reaction mixture was concentrated in vacuo to give 4a (8.90 mg,
57%, two steps). Spectral data for 4a: [α]25D = +87.8 (c 2.3, MeOH);
1H-NMR (500 MHz, DMSO-d6) δ
9.15 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.31 (d, J = 7.5 Hz, 1H), 8.28 (d, J = 7.5 Hz, 1H), 8.23 (t,
J = 5.7 Hz, 1H), 7.79 (br, 6H), 5.44 (dt, J = 12.6, 7.5 Hz, 1H), 5.34 (dt, J = 12.6, 7.5 Hz, 1H), 3.84 (d, J = 14.9
Hz, 1H), 3.80 (d, J = 15.5 Hz, 1H), 3.62-3.21 (m, 4H), 3.00–2.92 (m, 2H), 2.77–2.73 (m, 7H), 2.09–1.91 (m,
4H), 1.53–1.21 (m, 10H); 13C-NMR (125 MHz, DMSO-d6) δ 169.0, 164.5, 158.9, 158.8, 155.7, 155.6, 155.7,
155.6, 154.6, 154.3, 152.5, 151.2, 142.6, 142.4, 141.9, 141.2, 136.0, 135.9, 129.7, 128.5, 124.7, 124.6, 69.7, 66.9,
47.2, 47.1, 38.6, 36.6, 33.5, 33.4, 26.7, 26.2, 20.9, 11.5; HRMS (ESI, M + Na) calcd. for C37H44N12O10Na
839.3201, found 839.3196.
Compound 16b: To a solution of 15b (15.0 mg, 77.3 µmol) in THF-H2O (4:1, 2.5 mL) was added
EDCI (44.6 mg, 230 µmol) and HOBt (31.3 mg, 230 µmol) at room temperature. After stirring for
1 h, to the reaction mixture was added amine 14 (70.0 mg, 77.3 µmol). The mixture was stirred for
24 h and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl3, dried over
MgSO4, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column
chromatography on silica gel (CHCl3:MeOH = 80:1) to give 16b (32.7 mg, 39%). Spectral data for 16b:
[α]25D = −7.6 (c 1.7, CHCl3); 1H-NMR (500 MHz, DMSO-d6) δ 9.12 (s, 1H), 9.10 (s, 1H), 8.91 (s, 1H), 8.89
(s, 1H), 8.34–8.28 (m, 2H), 7.91 (t, J = 6.3 Hz, 1H), 6.78 (t, J = 5.7 Hz, 2H), 5.42 (dt, J = 12.6, 7.5 Hz, 1H),
5.32 (dt, J = 12.6, 7.5 Hz, 1H), 3.80 (d, J = 15.5 Hz, 1H), 3.75 (d, J = 14.9 Hz, 1H), 3.61–3.22 (m, 10H),
2.90–2.80 (m, 4H), 2.74 (s, 3H), 2.03 (br, 2H), 1.89 (br, 2H), 1.41–0.85 (m, 28H); 13C-NMR (125 MHz,
DMSO-d6) δ 169.3, 164.6, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5, 142.3, 141.7,
141.0, 136.0, 135.9, 129.8, 128.4, 124.8, 124.6, 79.2, 77.2, 70.1, 70.0, 69.3, 69.2, 50.0, 47.4, 47.2, 36.6, 33.5,
33.4, 29.2, 28.2, 29.1, 21.1, 21.0, 11.5; HRMS (ESI, M + Na) calcd. for C49H62N14O15Na 1109.4417,
found 1109.4387.
Compound 4b: To a solution of 16b (8.00 mg, 7.35 µmol) in MeOH (1 mL) was added 10% Pd/C
(10.0 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 min.
The reaction mixture was filtered through a pad of Celite® and eluted with CHCl3-MeOH (9:1).
The filtrates were concentrated in vacuo to give amine 17b, which was used without further purification.
The amine 17b was dissolved in CH2Cl2-TFA (2:1, 3 mL), and the resulting solution was stirred at
room temperature for 10 min. The reaction mixture was concentrated in vacuo to give 4b (2.03 mg,
32%, 2 steps). Spectral data for 4b: [α]25D = +58.2 (c 2.1, MeOH);
1H-NMR (500 MHz, DMSO-d6) δ 9.15
(s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.30 (d, J = 7.5 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.07
(br, 1H), 7.76 (br, 6H), 5.44 (dt, J = 12.6, 6.9 Hz, 1H), 5.35 (dt, J = 12.6, 7.5 Hz, 1H), 3.82–2.63 (m, 19H),
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2.09–1.87 (m, 4H), 1.53–1.22 (m, 10H); 13C-NMR (125 MHz, DMSO-d6) δ 169.5, 164.5, 162.4, 159.0, 158.8,
158.4, 158.1, 155.7, 155.6, 154.6, 154.4, 152.6, 151.2, 142.6, 142.4, 141.9, 141.2, 137.4, 136.0, 135.9, 129.7,
128.9, 128.5, 128.2, 125.4, 124.7, 124.6, 69.9, 69.3, 66.7, 47.2, 47.0, 38.6, 36.6, 33.5, 33.4, 26.8, 26.1, 21.1, 21.0,
20.9, 11.6; HRMS (ESI, M + Na) calcd. for C39H48N12O11Na 883.3463, found 883.3479.
Compound 19a: To a solution of 18a (9.60 mg, 47.6 µmol) in THF-H2O (2:1, 3 mL) was added EDCI
(27.4 mg, 143 µmol) and HOBt (19.3 mg, 143 µmol) at room temperature. After stirring for 1 h,
to the reaction mixture was added amine 14 (43.6 mg, 47.6 µmol). The mixture was stirred for 24 h
and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl3, dried over MgSO4,
and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column
chromatography on silica gel (CHCl3:MeOH = 10:1) to give 19a (40.0 mg, 76%). Spectral data for 19a:
[α]25D = −0.25 (c 1.0, CHCl3); 1H-NMR (500 MHz, DMSO-d6) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H), 8.90
(s, 1H), 8.32 (d, J = 8.0 Hz, 1H), 8.29 (d, J = 7.5 Hz, 1H), 8.12 (t, J = 6.3 Hz, 1H), 6.78 (t, J = 5.7 Hz, 2H),
5.42 (dt, J = 12.6, 7.5 Hz, 1H), 5.31 (dt, J = 12.6, 7.5 Hz, 1H), 3.77 (d, J = 15.5 Hz, 1H), 3.72 (d, J = 14.9 Hz,
1H), 3.62-3.24 (m, 4H), 2.84 (br, 4H), 2.74 (s, 3H), 2.36–1.88 (m, 17H), 1.33–1.03 (m, 28H); 13C-NMR
(125 MHz, DMSO-d6) δ 169.7, 164.5, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5,
142.3, 141.7, 141.0, 136.1, 136.0, 136.1, 135.9, 129.8, 128.5, 124.8, 124.7, 79.2, 77.3, 70.0, 68.5, 56.9, 54.7, 52.9,
47.4, 47.3, 45.7, 36.6, 33.4, 29.2, 28.2, 26.1, 21.1, 11.6; HRMS (ESI, M + Na) calcd. for C52H69N13O14Na
1122.4985, found 1122.4991.
Compound 5a: To a solution of 19a (6.70 mg, 6.01 µmol) in CH2Cl2 (2 mL) was added TFA (1 mL) at
room temperature, and the mixture was stirred for 10 min. The reaction mixture was concentrated in
vacuo to give 5a (5.14 mg, 95%). Spectral data for 5a: [α]25D = +85.6 (c 3.4, MeOH);
1H-NMR (500 MHz,
DMSO-d6) δ 9.16 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.32 (d, J = 7.5 Hz, 1H), 8.30 (d, J = 8.0 Hz,
1H), 8.04 (t, J = 6.3 Hz, 1H), 7.71 (br, 4H), 5.44 (dt, J = 12.6, 6.9 Hz, 1H), 5.34 (dt, J = 12.6, 7.5 Hz, 1H), 3.81
(d, J = 15.5 Hz, 1H), 3.76 (d, J = 14.9 Hz, 1H), 3.62–3.19 (m, 15H), 2.98 (br, 2H), 2.75 (br, 7H), 2.07–1.87
(m, 4H), 1.53–1.23 (m, 10H); 13C-NMR (125 MHz, DMSO-d6) δ 169.1, 164.5, 162.5, 159.0, 158.8, 158.5,
155.7, 155.6, 154.6, 154.4, 152.6, 151.2, 142.6, 142.4, 141.9, 141.2, 137.4, 136.0, 135.9, 129.8, 129.0, 128.5,
128.3, 125.4, 124.8, 124.7, 117.7, 115.3, 69.5, 47.3, 47.1, 38.6, 33.5, 33.4, 26.8, 26.7, 26.0, 21.1, 21.0, 11.5;
HRMS (ESI, M + H) calcd. for C42H54N13O10 900.4117, found 900.4098.
Compound 19b: To a solution of 18b (9.40 mg, 38.1 µmol) in THF-H2O (2:1, 3 mL) was added EDCI
(22.0 mg, 114 µmol) and HOBt (15.0 mg, 114 µmol) at room temperature. After stirring for 1 h,
to the reaction mixture was added amine 14 (34.9 mg, 38.1 µmol). The mixture was stirred for 24 h
and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl3, dried over MgSO4,
and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column
chromatography on silica gel (CHCl3:MeOH = 10:1) to give 19b (14.4 mg, 33%). Spectral data for 19b:
[α]25D = −6.7 (c 0.65, CHCl3); 1H-NMR (500 MHz, DMSO-d6) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H),
8.90 (s, 1H), 8.34-8.28 (m, 2H), 7.95 (t, J = 5.7 Hz, 1H), 6.78 (t, J = 5.7 Hz, 2H), 5.42 (dt, J = 12.6, 7.5 Hz,
1H), 5.32 (dt, J = 12.6, 7.5 Hz, 1H), 3.79 (d, J = 15.5 Hz, 1H), 3.73 (d, J = 15.5 Hz, 1H), 3.60–3.16 (m, 8H),
2.86–2.84 (m, 4H), 2.74 (s, 3H), 2.37–1.88 (m, 17H), 1.33–1.04 (m, 28H); 13C-NMR (125 MHz, DMSO-d6)
δ 1 169.9, 165.1, 163.0, 162.8, 159.4, 159.2, 156.2, 156.0, 155.0, 154.8, 153.0, 151.5, 143.0, 142.8, 142.2, 141.5,
136.6, 136.4, 130.3, 129.0, 125.3, 125.1, 79.7, 77.7, 70.5, 70.4, 69.9, 68.7, 57.7, 55.2, 53.5, 47.9, 47.7, 46.3,
37.1, 36.3, 34.0, 33.9, 29.7, 28.7, 26.6, 21.6, 21.5, 12.0; HRMS (ESI, M + Na) calcd. for C54H73N13O15Na
1166.5247, found 1166.5238.
Compound 5b: To a solution of 19b (14.4 mg, 12.6 µmol) in CH2Cl2 (2 mL) was added TFA (1 mL) at
room temperature, and the mixture was stirred for 10 min. The reaction mixture was concentrated in
vacuo to give 5b (11.2 mg, 94%). Spectral data for 5b: [α]25D = +29.7 (c 4.4, MeOH);
1H-NMR (500 MHz,
DMSO-d6) δ 9.15 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.31 (d, J = 7.5 Hz, 1H), 8.28 (d, J = 7.5 Hz,
1H), 8.02 (br, 1H), 7.73 (br, 4H), 5.45 (dt, J = 12.6, 7.5 Hz, 1H), 5.34 (dt, J = 12.6, 7.5 Hz, 1H), 3.80 (d,
J = 15.5 Hz, 1H), 3.76 (d, J = 15.5 Hz, 1H), 3.60–3.19 (m, 19H), 2.75 (br, 9H), 2.08–1.87 (m, 4H), 1.53–1.17
(m, 10H); 13C-NMR (125 MHz, DMSO-d6) δ 169.4, 164.5, 162.4, 158.8, 155.7, 152.7, 151.2, 141.9, 141.2,
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136.0, 128.9, 128.3, 124.8, 117.7, 115.3, 79.2, 69.9, 69.8, 69.3, 47.2, 47.1, 38.6, 33.5, 33.4, 26.8, 26.7, 26.1, 21.1,
21.0, 20.9, 11.5; HRMS (ESI, M + H) calcd. for C44H58N13O11 944.4379, found 944.4344.
3.3. FRET Melting Analysis
Fluorescence resonance energy transfer (FRET) melting assay was performed with an excitation
wavelength of 470–505 nm and a detection wavelength of 523–543 nm using the DNA Engine Option 2
Real-Time Cycler PCR detection system (Biorad, Hercules, CA, USA). The dual fluorescently labeled
oligonucleotides were used in this protocol (Table S1). The donor fluorophore was 6-carboxyfluorescein
(FAM) and the acceptor fluorophore was 6-carboxytetramethylrhodamine (TAMRA). All purified
nucleotides (Sigma Genosys, Tokyo, Japan) were dissolved as stock solutions (100 µM) in MilliQ water
to be used without further purification. Further dilutions of the oligonucleotides were performed
with a 60 mM potassium cacodylate buffer (pH 7.4), and FRET experiments were carried out with
a 0.4 µM oligonucleotide solution. Dual-labeled DNA was annealed by heating at 99 ◦C for 5 min,
and then slowly cooled to room temperature. Ligands were prepared as DMSO stock solutions
(10 mM) and diluted to 1 mM using DMSO, and then diluted to 100 µM using a 60 mM potassium
cacodylate buffer (pH 7.4). Next, the annealed DNA (20 µL, 0.4 µM) and the compound solution (20 µL,
2 µM) were distributed across 96-well plates (Takara), with a total volume of 40 µL, with the labeled
oligonucleotide (0.2 µM) and the compound (1.0 µM). The plates were incubated at 25 ◦C for 12 h.
Subsequent experiments used the following temperature procedure in RT-PCR, finishing as follows:
25 ◦C for 20 min, and then a stepwise increase of 1 ◦C every minute from 25 ◦C until 99 ◦C. During the
procedures, we measured the FAM fluorescence after each step. The change in the melting temperature
at 1.0 µM compound concentration (∆Tm (1.0 µM)) was calculated from at least three experiments by
subtraction of the blank from the averaged melting temperature of each compound.
3.4. CD Spectrometry
Circular Dichroism (CD) spectra were recorded on a J-720 spectropolarimeter (JASCO, Tokyo, Japan),
using a quartz cell of 1 mm optical path length and an instrument scanning speed of 500 nm/min with
a response time of 1 s, and over a wavelength range of 220–320 nm. The oligonucleotide telo24 used in this
protocol (Table S1) was dissolved as a 1.0 mM stock solution in MilliQ water, to be used without further
purification. Further dilution of the nucleotide was done with a 50 mM Tris-HCl buffer (without ions or
with 50 mM KCl) from 1 mM stock solutions, to give a concentration of 10 µM. The solution was annealed
by heating at 99 ◦C for 5 min, and then slowly cooled to room temperature, and then titrated into the
oligonucleotide samples up to 5 mol equivalents using ligands, and incubated overnight. Finally, the CD
spectra are representative of five averaged scans taken at 25 ◦C.
3.5. Computational Analysis
For the initial coordinates of compounds 3, 4, and 5, ionization and energy minimization were
performed by the OPLS3 force field in the LigPrep Script in the Maestro (Schrödinger, LLC, New York,
NY, USA). These minimized structures were employed as input structures for docking simulations.
The human telomeric G4 structures with parallel-type topologies (PDB ID: 1KF1 and 3UYH) were
refined for docking simulations using constrained energy refinements in the OPLS-AA force field
(Schrödinger LLC). Docking simulations were performed using the Glide [48,49] SP docking program
(Schrödinger, LLC, New York, NY, USA).
4. Conclusions
In conclusion, we have newly synthesized tri-substituted 6OTD derivatives 3–5 by introducing
aminoethyl, aminoethoxyethyl, and piperazinyethoxyethyl groups at C5 of L2H2-6M(2)OTD 1, respectively.
Among these ligands, 5b stabilizes telomeric G4 preferentially over c-kit and K-ras G4s. Docking studies
with parallel-type telomeric G4 revealed that the hexaoxazole moiety of 5b stacks with the G-quartet of
telomeric G4, and the newly introduced side chain efficiently interacts with the groove.
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